Indian-market tadalafil appears under several trade names, but the same active ingredient does not make every branded product an FDA-approved U.S. generic. Vidalista, Tadarise, Tadacip and Forzest are associated with different company records and product lines. A useful comparison therefore starts with verifiable name, active-ingredient claim, dosage form, declared strength and company role rather than online popularity or a seller’s assertions about faster performance.
Product evidence varies. Cipla lists Tadacip 20 mg in its corporate catalog, Sun Pharmaceutical Industries lists Forzest 20 mg, and Indian pharmacy records identify Megalis 5, 10 and 20 mg tablets with Macleods Pharmaceuticals as marketer. Sunrise Remedies documents Tadarise and combinations such as Super Tadarise; Centurion-associated Vidalista pages describe multiple forms but can contain conflicting fields. These differences in evidentiary strength should not be flattened into a shopping ranking.
This directory compares identities and shows where to read a brand-specific page. It does not sell foreign products, verify live stock or suggest importation. U.S. readers comparing medically appropriate therapy should distinguish these names from FDA-approved generic tadalafil and the Cialis brand. Only the exact approved product, lawful prescription and licensed U.S. pharmacy determine the domestic dispensing route.
The table emphasizes what can be established from a company-linked product listing, rather than pretending to audit an individual box bought from a reseller. A corporate catalog can support a reported branded product identity; it does not authenticate every package in circulation, verify every manufacturing lot or confirm FDA approval.
For differences among a company’s product variants, open the corresponding brand article. Each page separates single-agent tadalafil from products that add another active drug or use a different formulation.
| Brand | Company-linked evidence | Product distinction |
|---|---|---|
| Vidalista | Centurion-linked catalog describes tadalafil tablets and variants | Check CT/Professional/Super Active individually |
| Tadarise | Sunrise Remedies lists tadalafil strengths and alternate forms | Super/Top variants may add dapoxetine |
| Tadacip | Cipla catalog lists Tadacip 20 mg tablet | Restrict established claim to documented listing |
| Forzest | Sun Pharma India catalog lists Forzest 20 mg tablet | Do not confuse with its separate Modula 5 mg brand |
| Megalis | India-market Megalis 5, 10 and 20 mg tadalafil tablet records list Macleods as marketer | Distinguish tadalafil-only strengths from Megalis-D combination variants |
| Tazzle | Brand-specific company and composition need verification | Form and manufacturer role must be confirmed |
The company name next to a product can identify an application holder, brand owner, marketer, finished-dose manufacturer, distributor or exporter. A brand associated with a well-known Indian pharmaceutical company should not automatically be attributed to that company as the physical manufacturer of every advertised batch.
Credible product evidence should identify the claimed role precisely. Indian pharmacy records name Macleods Pharmaceuticals as marketer of Megalis 5, 10 and 20 mg; that should not be converted into proof about the physical factory for every lot. Other similarly branded products may have different manufacturers or additional active ingredients. When descriptions conflict, preserve the uncertainty rather than substituting a blanket brand claim.
For this directory, an ordinary tadalafil-only product is different from a tablet containing tadalafil plus dapoxetine or another active substance. The combination changes pharmacology, interactions and regulatory assessment. Sellers sometimes use similar prefixes or suffixes, which makes a family name insufficient to establish the exact ingredients.
For instance, Sunrise documents Super Tadarise as a tadalafil–dapoxetine combination, not merely a higher-strength plain tablet. India-market records also identify Megalis-D 10 mg/30 mg as tadalafil plus dapoxetine, distinct from Macleods-marketed single-ingredient Megalis tablets. Combination products should be verified separately and are not a substitute for an FDA-approved U.S. tadalafil ED prescription.
Conventional tadalafil tablets, chewable claims, orally dissolving presentations, soft capsules and oral-jelly advertisements may appear under related brand families. A marketed route or form does not establish that it is approved, absorbed identically or interchangeable with a standard U.S. tablet.
Centurion-associated Vidalista CT and Professional listings and Sunrise-associated Tadarise Oral Jelly or Effervescent listings illustrate why the product name must include its suffix and dosage form. Their marketed claims should be verified independently of the ordinary tablet record.
Some foreign catalogs display higher tadalafil strengths than the U.S. Cialis ED tablet presentations of 2.5, 5, 10 and 20 mg. That is a material difference in labeling context, not a sign of superior effectiveness. Higher figures should not be used to write an American prescribing guide or to imply suitability.
The U.S. tablet-strength catalog explains labeled presentations. A clinician selects the indication and dosing framework after considering cardiovascular health, interactions and other factors.
U.S. approval attaches to particular applications and products. For a generic to be treated as therapeutically equivalent to a reference medicine, the relevant regulatory requirements must be met. Use of the same chemical name by a foreign-market brand is not sufficient evidence.
An NDC or reference to FDA on a reseller page is not a substitute for checking the precise U.S. product record. More importantly, this directory does not claim that any listed foreign product can be lawfully dispensed as an approved generic in U.S. pharmacies.
Record the full trade name and suffix, ingredient declaration, strength, dosage form, pack information, company named on the label and claimed market authorization. Then compare those fields with credible product records, noting whether the information is company-published, independently corroborated or not yet verified.
If the strength or active-ingredient field conflicts across the same seller’s pages, do not resolve the mismatch by assuming the more attractive description is right. Mark the particular variant as unverified and avoid medical equivalence claims.
Any authentic product containing tadalafil raises the same ingredient-level contraindications with organic nitrates and riociguat. Cardiovascular disease, alpha blockers and interacting medicines remain relevant. An unverified foreign-market product introduces additional uncertainty about actual composition and manufacture.
Read tadalafil interactions and tadalafil side effects for the U.S. active-ingredient safety framework. These general facts must not be presented as clinical verification of a particular imported tablet.
Advertisements promising shipment of foreign tadalafil to U.S. addresses do not establish lawful importation, FDA authorization or legitimate dispensing. U.S. importation of unapproved prescription medicines is generally prohibited, subject to limited FDA enforcement discretion that should not be marketed as a routine purchase path.
For a U.S. patient, the relevant process is evaluation by an authorized clinician and dispensing from a licensed pharmacy. The tadalafil buying guide deals with that approved-product route, not foreign-brand fulfillment.
Use an individual brand page when the question concerns a company, a precise marketed strength or a variant such as Super Tadarise. Use the generic tadalafil guide when the question concerns FDA-approved U.S. generics. Use the main tadalafil ingredient hub for labeled clinical indications and regimen context.
This separation prevents an Indian-brand directory from repeating each product page or presenting foreign marketing facts as medical advice. Unverified items should remain clearly identified as such until product-specific evidence supports more definite statements.
They may share tadalafil as a claimed ingredient, but exact products, formulations and additional active ingredients differ and need product-level confirmation.
No. U.S. approval and therapeutic equivalence require their own product-specific regulatory evaluation.
Company-linked listings associate Vidalista with Centurion Laboratories and Tadarise with Sunrise Remedies; exact roles and packages still need verification.
No. Sunrise Remedies lists Super Tadarise as a tadalafil–dapoxetine combination rather than plain tadalafil.
Yes. Cipla lists a Tadacip 20 mg tadalafil tablet in its corporate product catalog; that fact does not establish U.S. approval.
Indian pharmacy records identify Megalis 5, 10 and 20 mg as tadalafil tablets marketed by Macleods. Separately, Megalis-D 10/30 mg is listed as a tadalafil–dapoxetine combination. These foreign-market listings do not prove U.S. FDA approval or interchangeable use.
No. Foreign strength listings do not replace the U.S. label or an individualized prescription.
Do not assume a routine lawful import route. U.S. patients should discuss FDA-approved options with a licensed clinician and pharmacy.